Advanced

Effect of the GLP-1 Receptor Agonist Lixisenatide on Counter-Regulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.

Farngren, Johan LU ; Persson, Margaretha LU and Ahrén, Bo LU (2016) In Diabetes Care 39(2). p.242-249
Abstract
Counter-regulatory responses are critical to prevent hypoglycemia in subjects with type 2 diabetes. This is particularly important in insulin-treated patients. This study explored the effect of the glucagon-like peptide 1 receptor agonist lixisenatide on the hormonal counter-regulatory responses to insulin-induced hypoglycemia when added to basal insulin therapy in subjects with type 2 diabetes.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Diabetes Care
volume
39
issue
2
pages
242 - 249
publisher
American Diabetes Association
external identifiers
  • pmid:26537183
  • wos:000368516200016
  • scopus:84962110250
ISSN
1935-5548
DOI
10.2337/dc15-1274
language
English
LU publication?
yes
id
65ce3d62-4824-495e-a916-ea9b57093ca5 (old id 8243127)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26537183?dopt=Abstract
date added to LUP
2015-12-02 22:56:59
date last changed
2017-08-27 03:17:53
@article{65ce3d62-4824-495e-a916-ea9b57093ca5,
  abstract     = {Counter-regulatory responses are critical to prevent hypoglycemia in subjects with type 2 diabetes. This is particularly important in insulin-treated patients. This study explored the effect of the glucagon-like peptide 1 receptor agonist lixisenatide on the hormonal counter-regulatory responses to insulin-induced hypoglycemia when added to basal insulin therapy in subjects with type 2 diabetes.},
  author       = {Farngren, Johan and Persson, Margaretha and Ahrén, Bo},
  issn         = {1935-5548},
  language     = {eng},
  number       = {2},
  pages        = {242--249},
  publisher    = {American Diabetes Association},
  series       = {Diabetes Care},
  title        = {Effect of the GLP-1 Receptor Agonist Lixisenatide on Counter-Regulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.},
  url          = {http://dx.doi.org/10.2337/dc15-1274},
  volume       = {39},
  year         = {2016},
}